Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases

OBJECTIVES: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in overall survival (OS) has been done in the last 25 years, with Cisplatin-Etoposide (PE) still considered the world-wide standard, with an average median survival of about 7–8 months in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, Corrado, Pagano, Maria, Baldi, Licia, Gnoni, Roberta, Braglia, Luca, Savoldi, Luisa, Zanelli, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427968/
https://www.ncbi.nlm.nih.gov/pubmed/25903963
http://dx.doi.org/10.1186/s12967-015-0491-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427968/
https://www.ncbi.nlm.nih.gov/pubmed/25903963
http://dx.doi.org/10.1186/s12967-015-0491-3

Ejemplares similares